Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorPhilip Polgreen
About this trial
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.
An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.
The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Eligibility criteria
Qualifiers
Previously tested and shown to be a CF carrier
English-speaking
Previously tested and shown to not be a CF carrier or CF patient
English-speaking
Disqualifiers
Currently sick with a respiratory infection
Prisoner Status
Unable to provide own written, informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
160 Participants
are grouped into 2 trial groupsLocations
1University of Iowa Hospitals and Clinics52242, Iowa CityIowa, United States
Sponsors and collaborators
Philip Polgreen
Lead sponsor
University of Iowa
Sponsor institution
National Institutes of Health (NIH)
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov